| Document |
Document Title |
|
WO/2023/225513A1 |
The present application relates to an effective dosage of an aqueous solution comprising an engineered AAT-Fc fusion dimeric protein for use in a method of treating or alleviating a symptom associated with aberrant serine protease activi...
|
|
WO/2023/217851A1 |
The present disclosure relates to compounds of Formula (I') that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventi...
|
|
WO/2023/218391A1 |
The present invention relates to an extract in eutectic solvent of olive oil polyphenols, as well as compositions or medical devices comprising it, in particular for use in medicine. The invention also relates to a process for the prepar...
|
|
WO/2023/219511A1 |
The invention relates to combination or composition comprising: (i) nicotinic acid or a derivative thereof, and (ii) a fatty acid or a derivative thereof selected from tetradecylthioacetic acid 5 (TTA) or a derivative thereof. The invent...
|
|
WO/2023/217879A1 |
The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
|
|
WO/2023/219106A1 |
The present invention addresses the problem of providing a solid derivative of 2-methyl-2-thiazoline that is easy to handle during formulation and is useful as an active pharmaceutical ingredient. The present invention provides: a 1,5-na...
|
|
WO/2023/217020A1 |
Disclosed in the present invention are an immunoglobulin κ-type light chain (Vκ4-1-IgLC) polypeptide having a unique Vκ4-1 and the use thereof. The amino acid sequence of the Vκ4-1-IgLC polypeptide is as shown in SEQ ID NO.1, and the...
|
|
WO/2023/220549A1 |
The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
|
|
WO/2023/218364A1 |
The present invention provides an anti-aging and anti-inflammatory composition comprising nicotinamide mononucleotide (NMN) or an analog thereof, and certain antioxidants, more specifically resveratrol and at least of ergothioneine and h...
|
|
WO/2023/216191A1 |
The present invention relates to a lip care product with a high shea oil content and a preparation method therefor. The lip care product comprises the following components: 50-60 wt% of a first shea oil, 19-24 wt% of a second shea oil, 7...
|
|
WO/2023/218201A1 |
The present invention relates to IKK-alpha inhibitory compounds, or a pharmaceutically acceptable salts, hydrates or solvates thereof, having the structural Formula (I), shown below: (I) wherein R1, X, R3 R4 and X1 are each as defined he...
|
|
WO/2023/217743A1 |
It is disclosed BTN3A inhibitory antibodies for use in treating gastro-intestinal inflammatory disorders, such as inflammatory bowel disease. The disclosure more specifically relates to specific anti-BTN3A antibodies that specifically bi...
|
|
WO/2023/220123A1 |
Disclosed herein are solid forms of a compound useful for modulating Cot. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms ...
|
|
WO/2023/217906A1 |
The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
|
|
WO/2023/217049A1 |
The present invention relates to a stilbene derivative as an AhR activator and use thereof. The compound of the present invention, or a pharmaceutically acceptable salt, a tautomer or a stereoisomer thereof has an excellent AhR activatio...
|
|
WO/2023/220338A1 |
The disclosure is in part directed to crystalline forms of N-(4-((2-methoxy-3-(1-(methyl-d 3)-1H-1,2,4-triazol-3-yl)phenyl) amino)-5-(propanoyl-3,3,3-d 3)pyridin-2-yl) cyclopropane carboxamide hydrochloride and pharmaceutical composition...
|
|
WO/2023/220741A1 |
The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulc...
|
|
WO/2023/220541A1 |
Tetrahydropyrido[3,4-d]pyrimidine compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly hum...
|
|
WO/2023/216753A1 |
The present invention relates to an imidazopyridazine derivative, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention are a compound as represented by formula (1)...
|
|
WO/2023/220715A1 |
The present disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutica...
|
|
WO/2023/213308A1 |
The present invention provides an amide-substituted heterocyclic compound or an isomer, a solvate, a deuterated derivative or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, R4, Ⓐ, L, L1, X, X1, and Y1 are defin...
|
|
WO/2023/214201A1 |
The method of obtaining stable suspensions of heterocrystals of titanium dioxide and particles of silicon dioxide and stable suspensions. Starting material is mixed with an aqueous solution of pharmaceutically acceptable acid, with subse...
|
|
WO/2023/214713A1 |
Disclosed is applicability in novel uses of a DO3A-based material containing a gadolinium complex as an antithrombotic agent or a coagulant, on the basis of a discovery finding that the DO3A-based material containing the gadolinium compl...
|
|
WO/2023/215186A1 |
Described herein is a method of reducing a sign or symptom of a dermal disorder in a subject in need of treatment for the dermal disorder by topically applying a topical silk fibroin composition once or more daily to the site of the derm...
|
|
WO/2023/215277A1 |
The present disclosure relates to trimeprazine for use in methods of treating trigeminal neuralgia and pain related thereto, by administering to a patient in need thereof a therapeutically effective amount of trimeprazine. The methods ma...
|
|
WO/2023/213909A1 |
The present invention relates to a composition comprising chondroitin sulfate and collagen hydrolysate, for use in ameliorating pain, preferably for use in ameliorating joint pain after exercise. The present invention furthermore relates...
|
|
WO/2023/213198A1 |
The present invention provides the following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, or metabolite thereof, and a pharmaceutical composition containing the compound of the present inventio...
|
|
WO/2023/214706A1 |
The present invention relates to a novel diaryl-propanedione derivative compound, a preparation method therefor, and a pharmaceutical composition comprising same for prevention or treatment of inflammatory or allergic diseases. More spec...
|
|
WO/2023/214280A1 |
An oral dosage form for controllable release and method of forming are described. The oral dosage form includes a core layer including an active ingredient and a plurality of outer shell layers surrounding the core layer, the plurality o...
|
|
WO/2023/214802A1 |
The present invention relates to a novel peptide comprising the sequence of the following general formula 1 or 2, and anti-inflammatory and regenerative uses thereof. [general formula 1] X-Gly-Ala-Tyr [general formula 2] Ala-X-Ser
|
|
WO/2023/214282A1 |
Provided is a composition comprising at least one terpene for use in modulation of a physiological function via at least one selected from the group consisting of agonism of a cannabinoid type 1 receptor (CB1R), modulation of agonism of ...
|
|
WO/2023/207949A1 |
The present invention provides a fused ring compound represented by formula I and use thereof. The fused ring compound of the present invention has a selective inhibitory activity against Nav1.8, and can be used as a Nav inhibitor and us...
|
|
WO/2023/211228A1 |
The present invention relates to a pharmaceutical composition comprising an anti-WARS1 antibody as an active ingredient. According to the results of administration of the anti-WARS1 antibody, according to the present invention, to a mous...
|
|
WO/2023/211229A1 |
The present invention relates to an anti-WARS1 antibody, and a pharmaceutical composition comprising same as an active ingredient. The anti-WARS1 antibody according to the present invention specifically binds to WARS1 and can inhibit the...
|
|
WO/2023/212160A1 |
This disclosure relates to drug releasing implants. In certain embodiments, the implants release drugs from a biodegradable material. In certain embodiments, the implant is a low swelling hydrogel. In certain embodiments, the drug is an ...
|
|
WO/2023/209678A1 |
The present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The present invention also relates to the derivatives of the said compound of Formula (I). The present invention relates to method of prep...
|
|
WO/2023/208112A1 |
The present disclosure provides an animal origin-free (for example, serum-free) cell sheet, such as a mesenchymal stem cell sheet, and a preparation method for the animal origin-free cell sheet. The present disclosure further provides us...
|
|
WO/2023/210767A1 |
Provided is a new technology for a chemical ligation reaction of oligonucleotides. When 2'-fluoro-5'-amino-nucleic acid (2F-5N nucleic acid) having a fluorine atom at the 2'-positon of 5'-amino-nucleic acid (5N nucleic acid) is synthesiz...
|
|
WO/2023/212233A1 |
The present disclosure relates to an animal food composition comprising a source of glycyrrhizin for use for preventing and/or treating allergic inflammatory skin diseases wherein the said animal food composition is formulated to provide...
|
|
WO/2023/208059A1 |
The present invention provides a thermosensitive modified chitin sponge drug-loaded implanted sustained-release system, a preparation method therefor, and use thereof. The system comprises the following components: a spongy matrix, the m...
|
|
WO/2023/208104A1 |
The present invention relates to an anti-human interleukin-4 receptor A antibody, a pharmaceutical composition thereof or a kit, and an application thereof in the treatment of eosinophilic esophagitis.
|
|
WO/2023/210670A1 |
The purpose of the present invention is to remove, prior to administration, particles in a solution preparation filled in a syringe. The present invention provides an injection preparation in which a solution is filled in a syringe, wher...
|
|
WO/2023/208106A1 |
The present invention provides a compound represented by formula (I), or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative, or a pharmaceutically acceptable salt thereof. The compound of the present invention is a n...
|
|
WO/2023/211198A1 |
The present invention relates to a novel immunoregulatory peptide having the ability to control inflammatory responses, and a use thereof. The peptide of the present invention may be useful in the treatment of inflammation, various immun...
|
|
WO/2023/209722A1 |
The invention relates generally to the field of compositions comprising one or more trehalose conjugates and is directed to methods of using the same such as for treating a disease or a disorder in a subject.
|
|
WO/2023/207545A1 |
The present invention provides an activated gain-of-function mutant of branched-chain amino acid transaminase 1 (BCAT1), and use thereof. In particular, the present invention provides a human BCAT1E61A gain-of-function activated mutant p...
|
|
WO/2023/212661A1 |
The SERPIN-derived peptides such as SP16 and SP163M can be used to treat a number of conditions associated with LRP1 mediation. There is a heed to develop novel SERPIN peptide derivatives to further improve the stability, bioavailability...
|
|
WO/2023/206055A1 |
Provided are a modification and the use of silk fibroin. Calcium in silk fibroin or fibroin fibers is partially or completely removed, so as to obtain the modified silk fibroin with a broad-spectrum antioxidant effect. A method for prepa...
|
|
WO/2023/208020A1 |
Disclosed are an intermediate of a polyamine derivative pharmaceutical salt, a preparation method therefor, and use thereof. The intermediate compound has the following structure: (I), which can be used to prepare a polyamine derivative ...
|
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
